This is a Phase 2a randomized, placebo-controlled multicenter study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 long haul pulmonary compromise.~COVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4.
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 long haul pulmonary compromise.